Business
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
- Company Presents Overviews of ACHIEVE and DELIVER Global Clinical Trials with Data Anticipated from Both Studies in the Second Half of 2023 - - FORCE™
About this update from Dyne Therapeutics, Inc.
[{"type":"text","content":"- Company Presents Overviews of ACHIEVE and DELIVER Global Clinical Trials with Data Anticipated from Both Studies in the Second Half of 2023 - - FORCE™ Platform Achieves Robust Exon Skipping, Restores Dystrophin at the Sarcolemma and Halts Progression of Fibrosis in a Severe In Vivo Model of Duchenne - WALTHAM, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced three poster presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 19-22, 2023, in Dallas, TX, and virtually. Overviews of the company’s global Phase 1/2 clinical trial designs will be presented in two poster sessions: ACHIEVE evaluating DYNE-101 for the treatment of myotonic dystrophy type 1 (DM1) and DELIVER evaluating DYNE-251 in males with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 51 skipping. Dyne anticipates reporting initial data from these clinical trials in the second half of 2023. In a separate poster presentation, new preclinical data showed that repeat monthly dosing with a mouse-specific FORCE conjugate (FORCE-M23D) achieved robust exon skipping in cardiac and skeletal muscles, dystrophin restoration, and improved skeletal muscle morphology in D2-mdx mice, a well-established preclinical model of DMD with a severe disease phenotype. Additionally, in the D2-mdx mice, starting FORCE-M23D treatment at six weeks of age led to lower deposition of fibrotic tissue compared with initiation at 14 weeks of age, indicating that earlier treatment with FORCE-M23D may lead to greater benefit. These data build upon Dyne’s comprehensive preclinical data and further support the company’s ongoing development in DMD. “We’re pleased to highlight for the muscle disease community our clinical trials in progress for our co-lead programs in DM1 and DMD where an urgent need exists for new and better treatment options,” said Wildon Farwell, M.D., MPH, chief medical officer of Dyne. “We look forward to sharing clinical data from our DELIVER and ACHIEVE trials in the second half of this year, furthering our goal to advance potentially transformative therapies for individuals living with these diseases.” Poste...